$JNJ still plans to submit its anti-BCMA CAR-T to FDA by the end of this year, but it pushed back its submission in EU to early 2021. 

Background on the therapy, which would compete with $BMY and $BLUE's ide-cel:

https://t.co/gh6mUjsHCp